Semaglutide changed everything. When Ozempic's weight loss effects became widely known in 2022–2023, it triggered a wave of medical weight loss clinic openings unlike anything the wellness industry had seen. By 2025, GLP-1-based weight management had become the fastest-growing clinical wellness category in the country, and franchise brands were moving quickly to stake out the space.
If you're evaluating a medical weight loss franchise opportunity — or wondering whether to add GLP-1 services to an existing wellness business — here's what the opportunity actually looks like: the business models, the economics, the regulatory landscape, and what separates franchises worth buying from ones that aren't.
What a Medical Weight Loss Franchise Actually Sells
The core offering at most GLP-1 clinics is a medically supervised weight loss program built around GLP-1 receptor agonist medications — primarily semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). Clients come in for an initial consultation, receive a medical evaluation, and are enrolled in a program that typically includes medication management, follow-up consultations, and some level of lifestyle coaching.
The reason the business model is compelling: clients who start GLP-1 medications don't stop quickly. The drugs address metabolic function, not willpower — and when clients discontinue them, most regain the weight. This creates strong retention and recurring revenue characteristics that look more like membership businesses than traditional healthcare encounters.
Telehealth-Only vs. Brick-and-Mortar
Medical weight loss franchises generally fall into two structural models:
Telehealth-first: Consultations happen via video, prescriptions are sent to mail-order pharmacies, and the client never visits a physical location. Overhead is dramatically lower — the main costs are technology, marketing, and physician or NP time. But this model faces increasing regulatory scrutiny, as several states have tightened rules around prescribing GLP-1 medications without in-person evaluations.
Brick-and-mortar clinic: Clients visit a physical location for initial consultation and periodic check-ins. Higher overhead but a stronger compliance position, better client experience, and an opportunity to sell additional services (body composition analysis, nutrition counseling, supportive supplements). Most franchise brands are moving toward this model or requiring a hybrid approach.
When evaluating a brand, understand clearly which model you're buying into — and what the regulatory trajectory looks like for that model in your target state.
The FDA and Compounding Pharmacy Landscape
The supply and regulatory environment for GLP-1 medications has been volatile, and any serious buyer needs to understand it.
When Ozempic and Wegovy experienced severe shortages starting in 2022, FDA regulations allowed compounding pharmacies to produce semaglutide as a shortage compound. This opened the door for medical weight loss clinics to offer semaglutide at prices dramatically lower than branded versions — typically $200–$400/month versus $1,000+ for brand-name drugs. This was a major driver of explosive growth in the category.
However, the FDA has since removed semaglutide from the shortage list, which in principle restricts compounding. The enforcement timeline and specific exemptions have shifted multiple times. Tirzepatide remains on shortage lists in some jurisdictions, giving some clinics an alternative pathway.
This is the biggest operational risk in the category. When evaluating a franchise, ask directly: what happens to our medication supply if compounding access is restricted in your state? Does the brand have branded drug access agreements or formulary alternatives? Franchises that have built resilient supply models are meaningfully different from those that haven't.
Unit Economics
When the supply and regulatory environment is stable, medical weight loss clinic economics are exceptional by wellness franchise standards:
- Monthly recurring revenue: A client on a GLP-1 program paying $350/month generates $4,200/year. A client base of 200 active program members generates $70,000/month in recurring revenue.
- Low equipment cost: Unlike med spas or cryotherapy franchises, there is no significant capital equipment to purchase. Initial investment is dominated by build-out, franchise fee, and working capital rather than devices.
- High service margin: Consultation fees, program enrollment fees, and medication margin are the primary revenue drivers.
- Physician leverage: Most clinics operate on an NP-led model with a physician medical director for oversight, allowing lean clinical staffing relative to revenue.
Total initial investment for a medical weight loss franchise typically ranges from $150,000 to $400,000 — meaningfully lower than a full med spa buildout. For context, the med spa franchise cost breakdown shows why equipment-heavy wellness categories carry higher barriers to entry.
The Staffing Model
The NP-led model is the dominant staffing structure in medical weight loss franchising. A Nurse Practitioner or Physician Assistant handles consultations and prescribes under their own prescriptive authority (in most states), with a physician medical director providing oversight and handling complex cases.
This keeps clinical labor costs manageable while satisfying the regulatory requirements for prescribing. The structure is similar to how many TRT clinic franchises staff their locations — clinical excellence without physician-level labor cost at every site.
What to Evaluate in a Medical Weight Loss Franchise
Beyond the standard FDD review that applies to any franchise (covered in our FDD guide for wellness franchise buyers), medical weight loss franchises have specific due diligence priorities:
- Medication supply strategy: Multiple pharmacy partners? What is the contingency if compounding access is restricted?
- Regulatory position by state: Some states have specific rules around GLP-1 prescribing and telehealth supervision requirements. Make sure the brand has operated in states with regulatory profiles similar to yours.
- Clinical protocols: How robust are the clinical decision-support tools? What is the process for clients who experience adverse effects? Thin protocols are a liability risk in a clinical category.
- Client retention programs: The revenue model depends on retention. What does the brand do to keep clients engaged? What is the actual retention rate in existing locations?
- Item 19 realism: Medical weight loss is a young franchise category with limited Item 19 data. Treat projections carefully — reporting locations may have had regulatory tailwinds that are now fading.
For a broader look at what clinical compliance infrastructure needs to look like at scale, our guide to franchise compliance software covers the systems that keep clinical wellness networks operating safely as they grow.
LynkPilot works with clinical wellness franchise networks on operational infrastructure — compliance tracking, MOR submission, and multi-location visibility. Book a walkthrough to see how it applies to clinical franchise operations.